Por favor, use este identificador para citar o enlazar este ítem:
https://doi.org/: 10.14670/HH-18-241
Twittear
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Yang, Xinxin | - |
dc.contributor.author | Geng, Jingshu | - |
dc.date.accessioned | 2022-12-16T12:41:24Z | - |
dc.date.available | 2022-12-16T12:41:24Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Histology and Histopathology Vol. 35, nº12 (2020) | es |
dc.identifier.issn | 0213-3911 | - |
dc.identifier.issn | 1699-5848 | - |
dc.identifier.uri | http://hdl.handle.net/10201/126586 | - |
dc.description.abstract | Ulcerative colitis (UC) is a serious form of inflammatory bowel disease (IBD) occurring worldwide. Although anti-TNF therapy is found to be effective in over 70% of patients with UC, nearly one-third are still deprived of effective treatment. Because glucocorticoids (GC) can effectively inhibit granulocyte-recruitment into the mucosa, cytokine secretion and T cell activation, they are used widely in the treatment of UC. However, remission is observed in only 55% of the patients after one year of steroid use due to a condition known as steroid response. Additionally, it has been noted that 20%-40% of the patients with UC do not respond to GC treatment. Researchers have revealed that the number of dendritic cells (DCs) in patients with UC tends to increase in the colonic mucosa. Many studies have determined that the removal of peripheral DCs through the adsorption and separation of granulocytes and monocytes could improve tolerance of the intestine to its symbiotic flora. Based on these results, further insights regarding the beneficial effects of Adacolumn apheresis in patients subjected to this treatment could be revealed. GC can effectively inhibit the activation of DCs by reducing the levels of major histocompatibility complex class II (MHC II) molecules, which is critical for controlling the recruitment of granulocytes. Therefore, alternative biological and new individualized therapies based on these approaches need to be evaluated to counter UC. In this review, progress in research associated with the regulatory effect of glucocorticoid receptors on DCs under conditions of UC is discussed, thus providing insights and identifying potential targets which could be employed in the treatment strategies against UC | es |
dc.format | application/pdf | es |
dc.format.extent | 11 | es |
dc.language | eng | es |
dc.publisher | Universidad de Murcia, Departamento de Biologia Celular e Histiologia | es |
dc.relation | Sin financiación externa a la Universidad | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Glucocorticoid receptors | es |
dc.subject | Dendritic cells | es |
dc.subject | Ulcerative colitis | es |
dc.subject.other | CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología | es |
dc.title | Glucocorticoid receptor modulates dendritic cell function in ulcerative colitis | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.doi | https://doi.org/: 10.14670/HH-18-241 | - |
Aparece en las colecciones: | Vol.35,nº12 (2020) |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Yang-35-1379-1389-2020.pdf | 6,84 MB | Adobe PDF | Visualizar/Abrir |
Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons